Immatics N.V. Namensaktie o.N.
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
61.18%
Market Cap
1.10 Bil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-1.61 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 8.19 G | 0 Units |
| PRICE DETERMINATION TIME | 07/16/2026 / 09:56:55 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 8.19 | 8.02 |
| PREV. DAY'S PRICE | 8.18 | (07/15) |
| CHANGE DAY BEFORE | +0.01 | 0.12 % |
| 52 WEEK HIGH / LOW | 10.16 (05/22) | 4.172 (09/01) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -1.20 | 0.14 | -1.61 | -1.83 | -1.67 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | 45.66 | - | - | - |
PRICE - BOOK RATIO | 3.59 | 1.45 | 2.48 | - | - |
PRICE - SALES RATIO | 14.53 | 4.50 | 23.58 | - | - |
PRICE - CASH FLOW RATIO | 43.04 | - | - | - | - |
Master Data
| WKN | A2P72S |
| ISIN | NL0015285941 |
| SYMBOL | 4A3 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | IMMATICS N.V. |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 134.10 Mil. |
| MARKET CAPITALISATION | 1.10 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| Performance | -6.19 % | 1.61 % | -11.76 % | -3.93 % | 61.18 % | -16.45 % | -18.20 % | -1.09 % |
| High | 8.87 | 10.07 | 10.16 | 10.16 | 10.16 | 12.70 | 14.38 | 10.16 |
| Low | 8.00 | 7.67 | 7.54 | 7.21 | 4.17 | 3.06 | 3.06 | 7.21 |
Dividende
pro Aktie
IMMATICS N.V. does not deliver dividend information
Company profile
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
(in 34 days)
08/19/26Q2 2026 Earnings Release
(in 55 days)
09/09/26Cantor Global Healthcare Conference
(in 124 days)
11/17/26Q3 2026 Earnings Release
(in 251 days)
03/24/27Q4 2026 Earnings Release
(in 306 days)
05/18/27Q1 2027 Earnings Release